Herpes simplex infection of the genitals is a common condition, more often due to herpes simplex virus (H5V) type 2 than to type 1 virus. There is a severe first attack followed by mild recurrences which are more common and more frequent after H5V-2 than after H5V-1 genital infection.
INTRODUCTION
Genital herpes simplex infection is due to herpes simplex virus (H5V) and can be classified into types 1 and 2 by monoclonal antibody staining which is more convenient than techniques such as endonuclease restriction cleavage". Genital herpes is usually due to H5V-2 while oro-labial and ophthalmic infections are usually due to H5V-1. Transmission of H5V occurs during close contact with an infected person shedding virus from an infected lesion or secretion. H5V enters through the mucous membrane, or small cracks or other skin lesions, and ascends sensory nerves to the root ganglia where it establishes latent infection. Latency follows clinical and subclinical initial infection; and H5V 2 has been isolated from 53 and 54 sensory root ganglia-.
Genital herpes has increased during recent years in a number of countries-. Its treatment may account for a large proportion of a clinic drug budget and a large proportion of non-salary expenditure, or may be a major expense for an infected individual. It is therefore timely to review the management of this condition.
CLINICAL FEATURES
Genital herpes is characterized by a severe first clinical attack followed by mild recurrences. The pattern of clinical features may allow an accurate clinical diagnosis, but this should be supported whenever possible by viral identification to maximize clinical acumen and ensure a firm basis for counselling, treatment, and partner notification.
In genital herpes simplex the incubation period between infection and the first clinical feature has been reported as 1-26 days with a mean around 7 days3-5, but may be much longer".
First episode

Primary attack
The first attack of genital herpes in someone who has had no previous H5V infection is severe, and is called the true primary attack. The age range at which this most commonly occurs is 18-25 years, the same as other sexually transmitted diseases (5TDs)7. Primary attacks often start with a prodrome comprising one to several days of malaise, fever, headache, general bone and muscle aches, root pains down the legs, and itch and irritation on the genitals. Widespread bilateral lesions appear on the genitals sometimes extending to the surrounding skin; they start as macules or maculopapules, rapidly become vesicles or vesicopustules, and ulcerate. Lesions appear in crops and are associated with lymphadenopathy developing a week or more after the lesions appear. Vaginal discharge may occur in women and urethral discharge in men. Lesions are sometimes seen on the cervix and rarely an acute necrotic cervicitis may be observed. Pharyngeal infection with a sore throat may occur. The whole episode takes a mean of 16.5 days in men and 19.5 days in women to complete re-epitheltalization-. A rise in titre of circulating antiherpes antibodies between acute and convalescent sera may support the diagnosis of a true primary attack-.
Non-primary first attack
When there has been previous infection with HSV the first attack is milder but follows a similar pattern. For example, this will occur when HSV-2 genital infection follows HSV-1 oro-labial infection. In practice it may not be possible or worthwhile to test for circulating antibodies; in these circumstances the first attack can be called first episode or more simply initial genital herpes. Initial attacks are worse in women than in men.
Recurrence
Though genital herpes simplex is common there are few good studies on frequency of recurrence. During the first 12 months after the initial attack recurrence occurs in 90% of people infected with HSV-2 and in 60% of those with HSV-1 genital infection. After HSV-2 primary infection, a median of 5 episodes a year occur in the first 2 years-. Recurrence in HSV-1 genital infection is less common.
The clinical pattern of a recurrent attack follows that of initial disease but is shorter. The prodrome lasts a few hours to 2 days, there is only one crop of lesions usually localized to an area about 1 cm in diameter, and healing is complete in 8-9 days". Recurrence may be more frequent in those who are anxious or under stress, may follow sexual intercourse, and in women may be related to the premenstruum or the onset of menstruationvv'", but attacks develop without any apparent precipitating factors. Episodes of symptoms may occur without lesions!'. Some women may fail to recognize recurrence and these episodes may be important in the spread of infection 12 •
Asymptomatic viral shedding
Between clinical recurrences HSV may occasionally be cultured from cervical swabs in women and urethral swabs in men, while virus may also be shed from lesions not visible on examination-. HSV-2 circulating antibodies are common among SID clinic attenders; in addition unrecognized HSV-21esions may occur more often among those with HSV-1 and HSV-2 antibodies, than patients with HSV-2 antibodies alone-'. According to one report asymptomatic cervical shedding mal be associated with inguinal lymphadenopathy 1 .
MANAGEMENT
Diagnosis
Laboratory methods
The first step in management is accurate diagnosis. Cell culture has been widely used but is time consuming and may be expensive. It is long established and is more sensitive and specific than other methods, so is the standard against which others are judged. Eighty per cent of positive cultures are detectable by visible cytopathic effect within 2 days, and more than 99% are detectable after 4 daysIs. Results may be available more rapidly by immunofluorescent or immunoperoxidase staining of cell cultures after 24 h 2 • Centrifugation-enhanced culture in shell vials also gives a result in 24 h and can be as sensitive as conventional cell culture and is highly specific-s, though not all laboratories have found it to be sensitive2. At present it is suggested as the most promising alternative to conventional isolation, and might produce savings for laboratories with heavy HSV workloads15.
Immunofluorescence with monoclonal antibodies has been reported to have a sensitivity of 74% and specificity of 85% compared with viral isolation but may be more reliable when specimens are taken early in the course of the illness!", Enzyme immunoassay may be more sensitive than immunofluorescence for it detects intracellular and extracellular antigens, unlike immunofluorescence where infected cells must be collected in clinical specimens for reliable results. In one report an enzyme immunoassay kit showed a sensitivity of 95% and specificity of 100%18. Results with immunofluorescence and enzyme immunoassay give results within a few hours. Latex agglutination and electronmicroscopy lack sensitivity compared to isolationvl". DNA probes and the polymerase chain reaction (PCR) are coming into use in clinical laboratories and give rapid results 1S ,20 and PCR may be especially applicable to cerebrospinal fluid 2o . Cytology is also quick, and though lacking in sensitivity (30-80%), it is specific', and is useful in less developed countries. Another technique is enzyme assay of the virus transport medium used to transfer a specimen to the laboratory, though this appears to lack sensitivity-".
Clinical diagnosis
The clinical features are often characteristic allowing accurate clinical diagnosis. The natural history of prodrome, vesicles and ulceration, noted by an observant patient, are almost pathognomic.
The widespread distribution and crops of lesions in initial disease, and characteristic grouped or clustered lesions in recurrence are highly suggestive. Vesicles on the genitals are rarely due to other causes.
Differential diagnosis
Common causes of genital ulceration include trauma with or without secondary infection and erosive balanitis, but unlike herpes they have no prodrome or vesicles. In men scabies cause itchy erosions. Primary syphilis is painless, persistent and nontender unless there is secondary infection. Chancroid is common in many tropical areas and causes painful tender ulcers; they have characteristic irregular margins and are associated with large inguinal nodes (buboes). In genital herpes the nodes are only moderately enlarged; though there may be mild erythema of the overlying skin the nodes do not suppurate unless there is secondary infection. 
General management (counselling)
Once the diagnosis has been established, the disease should be explained to patients, including the natural history, sexual transmission and avoidance of sexual contact when lesions are present or suspected, and risk of neonatal infection. Regular cervical cytogical smears are still recommended though HSV appears only to be a co-factor in the development of cervical and other intraepithelial neoplasias-t. As with all STDs partner change should be minimized, and at-risk partners should be notified that they should seek medical advice. Condoms should be recommended to minimize transmission of asymptomatically shed virus and recent publicity over human immunodeficiency virus infection has made them more acceptable.
Factors associated with recurrence must be discussed. Time spent counselling at this stage minimizes subsequent anxiety which may otherwise be disabling. Simple hygiene and counselling may be all that is required in patients with mild infrequent recurrences. Patients with initial attacks 25 • 26 . Acyclovir 5% cream 5 times daily till healing is complete or for a maximum of 10 days showed significant reductions in healing times and duration of viral shedding but had less effect on symptoms and new lesion formation than systemic therapy-", Intravenous therapy should be reserved for very severe initial disease and neurological complications, though it has only been studied in encephalitis. Oral therapy is suitable for all stages and all lesions. Cream should only be applied to skin lesions. Most patients with initial disease can be managed as outpatients provided they present early; women frequently have severe initial disease and routine treatment with oral acyclovir minimizes admission to hospital. A patient who presents early with an initial attack may appear to have mild disease but this may worsen without antiviral therapy. Cream may be suitable for men or women with a mild attack and external skin lesions.
Recurrent genital herpes
Recurrent genital herpes has a short course so therapy should start as soon as possible. Early studies of oral acyclovir failed to take account of this but statistically significant reductions in viral shedding, lesion duration and new lesion formation were reported-', Five per cent acyclovir cream also shortens healing times in recurrent disease-", Treatment of individual episodes has no effect on subsequent recurrence. So far there has been no report of sustained viral resistance after treatment in immunocompetent patients; resistant organisms have rarely been isolated during individual attacks and sensitive isolates have been recovered from the following episode-s.
Suppressive therapy
Five to 10% of patients with recurrent disease suffer frequent attacks (6-12 or more a year). Oral acyclovir 200 mg 2-5 times daily for 3 months to 3 or 4 years has been effective in suppressing frequent recurrence-". Multiple doses are more effective than infrequent dosing; for example, 200mg 4 times daily is more effective than 400 mg twice daily or 800 mg once daily30. In practice the daily dose should be reduced to the minimum that is effective for the individual. Therapy should be stopped every 6-12 months to reassess recurrence and the need for daily therapy. The treatment plan should be discussed with patients in advance so they understand that therapy will be stopped but restarted if required.
Abortive therapy
Another approach to patients with frequent recurrence is based on the method of treating individual attacks described by Forsbeck et al. 31 Patients carry acyclovir tablets with them at all times and begin therapy at the start of the firstsymptom. Formaximum effect time should be spent establishing the first symptom and identifying its onset. In this way 80% of recurrences may be aborted or shortened by at least 50%; oral acyclovir 200mg 5 times daily or 400 mg twice daily for 5 days appear equally effective".
Tolerance
Adverse effects are usually mild and infrequent. Intravenous therapy should be given by infusion rather than bolus injection to avoid crystalluria. Cream applied to large raw areas may give rise to burning related to the base and not the drug 29.
Several other guanine derivatives have been described and evaluated as inhibitors of herpes simplex virus in cell cultures and animal infections; one compound currently under clinicaltrial in human subjects is a prodrug, famcyclovir(Smith Kline Beecham)32,33.
COMPLICAnONS
Complications in immunocompetent patients include urinary difficulty and retention-", encephalitis with HSV-l and meningitis with HSV-2, and rarely hepatitis, pneumonia, thrombocytopenia, or other neurological disease'. There may also be a link with subsequent intraepithelial neoplasia and carcinoma though human papillomavirus appears to have a more important causative role 22,3!;.
Pregnancy
The natural history of genital herpes is rarely altered by pregnancy. A few cases of dissemination with primary infection during pregnancy have been reported. Primary infection in the first trimester has rarely been associated with spontaneous abortion-", Estimations of primary HSV-2 infection per 1000 pregnancies in London were reported as 2.4 in Asian women, 5 in white women and 20 in black women". The main risk to the fetus is when a mother close to term develops primary genital herpes. This may be followed by premature labour, intrauterine growth retardation, and neonatal intection'". Infection usually occurs during vaginal delivery and may affect 1: 3000 to 1: 20,000 live births-,
Delivery
When there is primary infection at parturition, Caesarian section should be considered for the risk of transmission to the fetus dUrin~vaginal delivery has been estimated as 20-50% . When there is a history of recurrence careful clinical examination should be undertaken at the beginning of labour. If lesions are present specimens for laboratory investigation should be collected and Caesarian section considered though the probability of fetal infection during vaginal delivery is only 0-8%39. Further development of rapid sensitive specific cheap easy laboratory detection of HSV will allow more rational management. Repeated virological screening during the last few weeks of pregnancy is no longer recommended as it fails to identify those at risk, and is not cost effective 40 ,41. Recently a plea was made for large scale detailed studies of women with and without genital herpes to give sound data to provide a basis for reducing neonatal herpesv, Such studies would need to be multicentre and in countries with more cases than Britain.
Acyclovir is not licensed for use in pregnancy but has been given to more than 100 women without untoward effects! while anecdotal reports indicate many more women have received the drug without adverse effects to the fetus. Systemic therapy has been advised for disseminated visceral infection in pregnancy as this carries a high mortality-.
Neonatal infection
Skin, eye and mouth disease affects 35% of infected neonates who have a good prognosis, encephalitis plus or minus skin eye or mouth disease affects 33% who have an intermediate prognosis, and disseminated disease affects the remainder who have a poor prognosis 36 .43 . When neonatal infection is suspected energetic management is indicated. Specimens for laboratory confirmation should be taken at once and intravenous acyclovir (10 mg per kg bodyweight B hourly) started without delay44.
GENITAL HERPES AND HUMAN IMMUNODEFICIENCY VIRUS INFECTION
HSV infection at any site may reactivate in human immunodeficiency virus (HIV) infection, and the more advanced the HIV disease the worse is the herpes. Chronic and progressive herpetic disease is a feature. Intravenous and oral acyclovir control individual attacks though higher doses for longer courses may be needed. Continuous oral therapy may be required. Though no controlled studies have been reported to help to decide optimum regimens, acyclovir 400mg orally 3 or 4 times daily has proved effective".
